Citations

Clear

11 citation(s) found for "Cao, Yang".

Fluorescence In Situ Hybridization Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Testing Results From the College of American Pathologists/American College of Medical Genetics Cytogenetics Committee
Peterson, Jess F., Tang, Guilin, Mixon, Christopher, Zepeda-Mendoza, Cinthya J., Sukov, William R., Zou, Ying S., Nusapan, Rangsinee, Tan, Julian, Dvorak, James, Velagaleti, Gopalrao V., Fang, Min, Levy, Brynn, Miron, Patricia M., Cao, Yang, Astbury, Caroline, Gardner, Juli-Anne, Peterson, Jess F. , Tang, Guilin , Mixon, Christopher , Zepeda‐Mendoza, Cinthya , Sukov, William R. , Zou, Ying S , Nusapan, Rangsinee , Dvorak, James, Velagaleti, Gopalrao V.N. , Fang, Min , Miron, Patricia Minehart , Astbury, Caroline , Gardner, Juli-Anne

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 16, 2026 | Volume: 150 | Issue: 12 | Pages: 942-947

10.5858/arpa.2026-0083-cp | PMID 42457191 Get It

Context.— One objective of the College of American Pathologists/American College of Medical Genetics Cytogenetics Committee is to ensure the accurate detection and clinical interpretation of abnormalities observed by fluorescence in situ hybridization (FISH) analysis when evaluating hematologic neoplasms. Objective.— To report a 20-year performance summary (2005–2024) of FISH challenges focusing on hematologic neoplasms. Design.— A retrospective review was performed from 2005 through 2024 to identify FISH challenges specifically addressing hematologic neoplasms. The overall performance of participants was evaluated to identify potential recurring errors of clinical relevance. Results.— A total of 124 hematologic neoplasm FISH challenges from 2005 to 2024 were provided to participating laboratories, including 45 paper challenges (results and/or images were provided for interpretation purposes), 43 liquid challenges (bone marrow aspirate or peripheral blood), and 36 formalin-fixed, paraffin-embedded (FFPE) tissue challenges. Of the 124 challenges, 120 (97%) exceeded the required 80% consensus for grading purposes. Of the 4 failed challenges (3%), 2 (1 liquid, 1 paper) involved the interpretation of atypical FISH signal patterns; 1 (paper) involved the interpretation of FISH signal patterns correlating involvement by myeloid versus lymphoid interphase nuclei; and 1 (liquid) likely involved a specimen processing or handling error that resulted in discordant participant responses. All 36 FFPE tissue challenges exceeded the 80% consensus for grading purposes. Conclusions.— This 20-year retrospective review demonstrates that clinical cytogenomic laboratories have been and continue to be highly proficient in the detection and interpretation of FISH abnormalities associated with hematologic neoplasms.
Current and Future Utilization of Optical Genome Mapping: Insights From the 2024 College of American Pathologists Supplemental Questionnaire
Gardner, Juli-Anne, Nusapan, Rangsinee , Tan, Julian, Levy, Brynn , Fang, Min , Velagaleti, Gopalrao V.N. , Cao, Yang , Astbury, Caroline , Mixon, James Christopher, Souers, Rhona J., Tang, Guilin , Peterson, Jess F. , Zou, Ying

Mayo Clinic

Archives of Pathology & Laboratory Medicine | November 27, 2025 | Volume: 150 | Issue: 5 | Pages: 354-359

10.5858/arpa.2025-0472-cp | PMID 41308031 Get It

Context.— Optical genome mapping (OGM) represents a promising cytogenomic technology that detects structural variants, including fusions, rearrangements, copy number variants, and loss of heterozygosity, in a single assay. Unlike karyotyping, fluorescence in situ hybridization, or chromosomal microarray, OGM leverages long-molecule imaging to map the whole genome with high resolution. This positions OGM as a novel tool for constitutional and somatic/cancer genomics. However, its current and planned utilization in clinical and research settings remains unknown, necessitating further investigation. Objective.— To investigate the current utilization of OGM in clinical and research laboratories, assess its applications, and evaluate future utilization strategies. Design.— In 2024, a supplemental questionnaire was incorporated into 6 College of American Pathologists proficiency testing programs to evaluate OGM’s utilization. Results.— Of 921 returned questionnaires, 712 were analyzed after duplicates were removed. Sixty-seven (9.4%) currently offered OGM testing: 5.2% (37) for research only, 1.8% (13) for only clinical use, and 2.4% (17) for both. Future adoption plans showed 7.6% (53 of 700 laboratories) and 7.9% (55 of 700 laboratories) aiming to implement OGM clinically within 12 and 24 months, respectively. The most common applications included hematologic malignancies and constitutional/germline postnatal disorders, followed by prenatal testing. International laboratories demonstrated statistically higher utilization rates than domestic laboratories ( P = .001). Conclusions.— This first survey on OGM clinical utilization reveals its status as a niche technology, with 67 laboratories currently using it. Its primary clinical applications are in constitutional/germline analysis and hematologic malignancies. Although international laboratories led in 2024, 108 laboratories (domestic and international) plan clinical adoption within 24 months, signaling OGM’s potential for broader integration.
Targeting IGF1 ‐Induced Cellular Senescence to Rejuvenate Hair Follicle Aging
Wang, Yang , Yang, Jian , Luo, Yue , Zhao, Zhiqiang , Yuan, Yawen, Li, Juan , Liu, Yang, Xu, Xiaoke , Lan, Yuankunyu, Zou, Juan , Li, Qintong , Pan, Yang , Yang, Yuanhan, Xiong, Muzhao, Li, Jinsong , Li, Weiyuxin , Cao, Yang , Zhu, Yi , Yang, Jian , Zhu, Yi , Xiao, Zhi‐Xiong Jim , Liu, Yang, Yi, Yong , Lan, Yuankunyu, Zou, Juan, Wang, Liang , Yang, Yuanhan, Wu, Min Cong , Zhang, Yujun

Mayo Clinic

Aging Cell | March 31, 2025 | Volume: 24 | Issue: 7 | Pages: No page available

10.1111/acel.70053 | PMID 40159808 Get It

ABSTRACT The insulin‐like growth factor‐1 (IGF‐1) signaling pathway is known as a potent aging modifier, disruption of which consistently associates with lifespan extension across diverse species. Despite this established association, the mechanisms by which IGF‐1 signaling modulates organ aging remain poorly understood. In this study, we assessed age‐related changes in IGF‐1 expression across multiple organs in mice and identified a more prominent increase in skin IGF‐1 levels with aging—a phenomenon also observed in human skin. To explore the consequences of elevated IGF‐1, we developed transgenic mice ectopically expressing human IGF‐1 in the epidermis, driven by the bovine keratin 5 promoter (IGF‐1 Tg). These mice exhibited premature aging of hair follicles, as evidenced by accelerated hair graying and loss. Single‐cell RNA sequencing analyses of dorsal skin highlighted an upsurge in cellular senescence markers and the senescence‐associated secretory phenotype (SASP) in hair follicle stem cells (HFSCs), alongside a decline in hair growth and HFSC exhaustion. Our findings indicate that excessive IGF‐1 triggers HFSC senescence, thereby disrupting hair follicle homeostasis. Remarkably, interventions in IGF‐1 signaling via downstream mechanisms—specifically blocking Ac‐p53 activation via SIRT1 overexpression or senolytic treatment for senescent cell clearance, or reducing IGF‐1 through dietary restriction—significantly reduced senescence markers, mitigated premature hair follicle aging phenotypes, and restored the stem cell pool. Our findings provide fundamental insights into the biological processes of hair aging and highlight the therapeutic promise of targeted interventions to rejuvenate aged HFSCs and promote hair follicle health.
Discovery of a MET-driven monogenic cause of steatotic liver disease
Wagenknecht, Jessica B. , Jorge, Salomão Dória , Tian, Shulan , Luehrs, Anthony C. , Assuncao, Thiago M. de , Cao, Yang , Klee, Eric W. , Vairo, Filippo , Urrutia, Raúl , Vairo, Filippo Pinto e , Zimmermann, Michael T. , Vierkant, Robert A. , Mathison, Angela , Atwal, Paldeep S , Allen, Alina M. , Lazaridis, Konstantinos N.

Mayo Clinic

Hepatology | January 29, 2025 | Volume: 82 | Issue: 6 | Pages: 1512-1522

10.1097/hep.0000000000001249 | PMID 39879586 Get It

Background and Aims: Metabolic dysfunction–associated steatotic liver disease affects about a third of adults worldwide and is projected soon to be the leading cause of liver cirrhosis. It occurs when fat accumulates in hepatocytes and can progress to metabolic dysfunction–associated steatohepatitis, liver cirrhosis, and HCC. Metabolic dysfunction–associated steatotic liver disease pathogenesis is believed to involve a combination of genetic and environmental risk factors. Single nucleotide polymorphisms have been implicated, but non-syndromic monogenic causes are lacking. Approach and Results: We identified a novel genetic variant in a familial case of metabolic dysfunction–associated steatohepatitis and performed deep variant functional analysis, including protein modeling, dynamics, and cell-based assays to assess molecular mechanisms of dysfunction and altered cellular signaling. We analyzed exome sequencing data of 3904 individuals with steatotic liver disease (SLD) to identify additional cases and establish the link between specific gene variants and SLD diagnosis. We discovered and functionally validated the NM_000245.4:c.3505A>T; p.(Ile1169Phe) variant in the MET (mesenchymal-epithelial transition) kinase domain as a monogenic cause of SLD. Subsequently, we detected additional ultra-rare, previously uninterpreted, and likely deleterious variants in MET from screening sequencing data. Among individuals with confirmed SLD based on electronic record review, 1.1% (45/3904) had rare predicted deleterious MET variants. Eight of 45 (17.7%) individuals had predicted deleterious variants in the MET kinase domain confirmed to be functionally like the familial case variant. Conclusions: We report the first germline nonmalignant rare MET -driven disease, a monogenic form of SLD.
Conventional Cytogenetic Analysis of Solid Tumor Abnormalities: A 25-Year Review of Proficiency Test Results from the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee
Vanderscheldon, Rachel K., Sukov, William R. , Gardner, Juli-Anne, Rehder, Catherine , Levy, Brynn , Velagaleti, Gopalrao V.N. , Toydemir, Reha M. , Tang, Guilin , Boles, Brittany , Cao, Yang , Mixon, Christopher , Zou, Ying , Astbury, Caroline , Tsuchiya, Karen D. , Peterson, Jess F. , Rehder, Catherine W , Zou, Ying S , Peterson, Jess F , Tsuchiya, Karen D , Tang, Guilin

Mayo Clinic

Genes | December 17, 2024 | Volume: 15 | Issue: 12 | Pages: 1612

10.3390/genes15121612 | PMID 39766879 Get It

Background: The joint College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee works to ensure the competency and proficiency of clinical cytogenetic testing laboratories through proficiency testing (PT) programs for various clinical tests offered by such laboratories, including the evaluation of cytogenetic abnormalities in solid tumors. Methods: Review and analyze 25 years (1999–2023) of solid tumor chromosome analysis PT results, utilizing G-banded karyograms. A retrospective review of results from 1999 to 2023 was performed, identifying the challenges addressing solid tumors. The chromosomal abnormalities and overall performance were evaluated. Results: A total of 21 solid tumor challenges were administered during the period 1999–2018. No solid tumor challenges were administered during the period 2019–2023. Challenges consisted of metaphase images and accompanying clinical history for the evaluation of numerical and/or structural abnormalities. All 21 cases reached 80% grading consensus for abnormality recognition. However, five cases (24%) failed to reach consensus for nomenclature reporting by participating laboratories. These cases illustrate errors in reporting chromosomal abnormalities, including whole-arm translocations and those involving sex chromosomes. In addition, they highlight the challenges with differentiation of terminal and interstitial deletions, difficulties in identifying correct breakpoints, and omission of brackets in neoplastic cases. Conclusions: This comprehensive 25-year review demonstrates the exceptional proficiency of cytogenetic laboratories in accurately identifying chromosome abnormalities in solid tumors, while also highlighting the challenges of reporting specific types of chromosomal abnormalities.
Conventional Cytogenetic Analysis of Constitutional Abnormalities: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee
Boles, Brittney, Gardner, Juli-Anne, Rehder, Catherine , Levy, Brynn , Velagaleti, Gopalrao V.N. , Sukov, William R. , Larson, Daniel P. , Cao, Yang, Mixon, Christopher , Vanderscheldon, Rachel K., Astbury, Caroline , Tsuchiya, Karen D. , Boles, Brittany , Toydemir, Reha M. , Cao, Yang, Zou, Ying , Peterson, Jess F.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | June 5, 2024 | Volume: 149 | Issue: 3 | Pages: 211-216

10.5858/arpa.2024-0048-cp | PMID 38838342 Get It

Context.— The joint College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee works to ensure competency and proficiency of clinical cytogenetics testing laboratories through proficiency testing programs for various clinical tests offered by such laboratories, including the evaluation of constitutional abnormalities. Objective.— To review and analyze 20 years of constitutional chromosome analysis proficiency testing results (2003–2022), primarily utilizing G-banded karyograms. Design.— A retrospective review of results from 2003 through 2022 was performed, identifying challenges addressing constitutional disorders. The chromosomal abnormalities and overall performance were evaluated. Results.— A total of 184 cases from 161 proficiency testing challenges were administered from 2003 through 2022. Challenges consisted of metaphase images and accompanying clinical history for evaluation of numerical and/or structural abnormalities. Of the 184 cases, only 2 (1%) failed to reach an 80% grading consensus for recognition of the abnormality. Both cases illustrated the limitations of correctly characterizing some chromosomal abnormalities, including recombinant chromosomal abnormalities and isochromosome identification. In addition, 2 cases failed to reach a consensus for nomenclature reporting: 1 with an isochromosome and another with a duplication. Conclusions.— This 20-year review illustrates the high rate of competency and proficiency of cytogenetic laboratories in the correct identification of constitutional chromosome abnormalities.
Investigating the link between frailty and outcomes in geriatric patients with isolated rib fractures
Mohseni, Shahin , Forssten, Maximilian Peter , Ismail, Ahmad Mohammad , Sarani, Babak , Ribeiro, Marcelo AF, Mohammad Ismail, Ahmad , Sarani, Babak , Mohseni, Shahin , Cao, Yang , Hildebrand, Frank

Mayo Clinic

Trauma Surgery & Acute Care Open | February 8, 2024 | Volume: 9 | Issue: 1 | Pages: e001206

10.1136/tsaco-2023-001206 | PMID 38347893 Get It

Background Studies have shown an increased risk of morbidity in elderly patients suffering rib fractures from blunt trauma. The association between frailty and rib fractures on adverse outcomes is still ill-defined. In the current investigation, we sought to delineate the association between frailty, measured using the Orthopedic Frailty Score (OFS), and outcomes in geriatric patients with isolated rib fractures. Methods All geriatric (aged 65 years or older) patients registered in the 2013–2019 Trauma Quality Improvement database with a conservatively managed isolated rib fracture were considered for inclusion. An isolated rib fracture was defined as the presence of ≥1 rib fracture, a thorax Abbreviated Injury Scale (AIS) between 1 and 5, an AIS ≤1 in all other regions, as well as the absence of pneumothorax, hemothorax, or pulmonary contusion. Based on patients’ OFS, patients were classified as non-frail (OFS 0), pre-frail (OFS 1), or frail (OFS ≥2). The prevalence ratio (PR) of composite complications, in-hospital mortality, failure-to-rescue (FTR), and intensive care unit (ICU) admission between the OFS groups was determined using Poisson regression models to adjust for potential confounding. Results A total of 65 375 patients met the study’s inclusion criteria of whom 60% were non-frail, 29% were pre-frail, and 11% were frail. There was a stepwise increased risk of complications, in-hospital mortality, and FTR from non-frail to pre-frail and frail. Compared with non-frail patients, frail patients exhibited a 87% increased risk of in-hospital mortality [adjusted PR (95% CI): 1.87 (1.52-2.31), p<0.001], a 44% increased risk of complications [adjusted PR (95% CI): 1.44 (1.23-1.67), p<0.001], a doubling in the risk of FTR [adjusted PR (95% CI): 2.08 (1.45-2.98), p<0.001], and a 17% increased risk of ICU admission [adjusted PR (95% CI): 1.17 (1.11-1.23), p<0.001]. Conclusion There is a strong association between frailty, measured using the OFS, and adverse outcomes in geriatric patients managed conservatively for rib fractures.
Screening Performance of S100 Calcium-Binding Protein B, Glial Fibrillary Acidic Protein, and Ubiquitin C-Terminal Hydrolase L1 for Intracranial Injury Within Six Hours of Injury and Beyond
Trivedi, Dhanisha , Forssten, Maximilian Peter , Czeiter, Endre , Amrein, Krisztina , Büki, András , DeSoucy, Erik, Cao, Yang , Ismail, Ahmad Mohammad , Kobeissy, Firas , Wang, Kevin , DeSoucy, Erik S. , Mohseni, Shahin

Mayo Clinic

Journal of Neurotrauma | December 20, 2023 | Volume: 41 | Issue: 3-4 | Pages: 349-358

10.1089/neu.2023.0322 | PMID 38115670 Get It

Development and Validation of an XGBoost-Algorithm-Powered Survival Model for Predicting In-Hospital Mortality Based on 545,388 Isolated Severe Traumatic Brain Injury Patients from the TQIP Database
Cao, Yang , Forssten, Maximilian Peter , Montgomery, Scott , Montgomery, Scott , Sarani, Babak , Mohseni, Shahin

Mayo Clinic

Journal of Personalized Medicine | September 19, 2023 | Volume: 13 | Issue: 9 | Pages: 1401

10.3390/jpm13091401 | PMID 37763168 Get It

Background: Traumatic brain injury (TBI) represents a significant global health issue; the traditional tools such as the Glasgow Coma Scale (GCS) and Abbreviated Injury Scale (AIS) which have been used for injury severity grading, struggle to capture outcomes after TBI. Aim and methods: This paper aims to implement extreme gradient boosting (XGBoost), a powerful machine learning algorithm that combines the predictions of multiple weak models to create a strong predictive model with high accuracy and efficiency, in order to develop and validate a predictive model for in-hospital mortality in patients with isolated severe traumatic brain injury and to identify the most influential predictors. In total, 545,388 patients from the 2013–2021 American College of Surgeons Trauma Quality Improvement Program (TQIP) database were included in the current study, with 80% of the patients used for model training and 20% of the patients for the final model test. The primary outcome of the study was in-hospital mortality. Predictors were patients’ demographics, admission status, as well as comorbidities, and clinical characteristics. Penalized Cox regression models were used to investigate the associations between the survival outcomes and the predictors and select the best predictors. An extreme gradient boosting (XGBoost)-powered Cox regression model was then used to predict the survival outcome. The performance of the models was evaluated using the Harrell’s concordance index (C-index). The time-dependent area under the receiver operating characteristic curve (AUC) was used to evaluate the dynamic cumulative performance of the models. The importance of the predictors in the final prediction model was evaluated using the Shapley additive explanations (SHAP) value. Results: On average, the final XGBoost-powered Cox regression model performed at an acceptable level for patients with a length of stay up to 250 days (mean time-dependent AUC = 0.713) in the test dataset. However, for patients with a length of stay between 20 and 213 days, the performance of the model was relatively poor (time-dependent AUC < 0.7). When limited to patients with a length of stay ≤20 days, which accounts for 95.4% of all the patients, the model achieved an excellent performance (mean time-dependent AUC = 0.813). When further limited to patients with a length of stay ≤5 days, which accounts for two-thirds of all the patients, the model achieved an outstanding performance (mean time-dependent AUC = 0.917). Conclusion: The XGBoost-powered Cox regression model can achieve an outstanding predictive ability for in-hospital mortality during the first 5 days, primarily based on the severity of the injury, the GCS on admission, and the patient’s age. These variables continue to demonstrate an excellent predictive ability up to 20 days after admission, a period of care that accounts for over 95% of severe TBI patients. Past 20 days of care, other factors appear to be the primary drivers of in-hospital mortality, indicating a potential window of opportunity for improving outcomes.
Two cases with de novo 3q26.31 microdeletion suggest a role for FNDC3B in human craniofacial development
Mitchell, Elyse, Gorski, Jerome L., Hollinger, Cassandra, Hoppman, Nicole L., Mitchell, Elyse B, Cao, Yang

Mayo Clinic

American Journal of Medical Genetics Part A | August 19, 2016 | Volume: 170 | Issue: 12 | Pages: 3276-3281

10.1002/ajmg.a.37892 | PMID 27541078 Get It

Here, we report strong evidence for a role of the FNDC3B gene in craniofacial development. Chromosomal microarray identified deletions at 3q26.31 in two patients with dysmorphic facial features. Parental FISH studies demonstrated that they are de novo; therefore, these two 3q26.31 microdeletions likely contribute to the patients' dysmorphic features. Interestingly, the minimal region of overlap contains only the FNDC3B gene. Ffibronectin domain III‐containing protein 3B (FNDC3B), also known as factor for adipocyte differentiation‐104 (FAD104), was first identified as a positive regulator of adipogenesis in a mouse model. Excitingly, further studies in a mouse model have recently demonstrated that FNDC3B is required for normal calvarial bone formation and negatively regulated calvarial cell differentiation through inhibition of BMP/Smad signaling. fndc3b‐deficient mice have multiple cranial and skeletal malformations, such as craniosynostosis‐like premature calvarial ossification, and skeletal deformities in the anterior fontanel and femurs. In summary, we report the first two patients with de novo 3q26.31 microdeletions. Both have dysmorphic features, consistent with the phenotypes seen in fndc3b‐deficient mice in animal studies, which imply a critical role of FNDC3B in human craniofacial development. © 2016 Wiley Periodicals, Inc.